Cost-effectiveness of pneumococcal conjugate vaccine: An update after 7 years of use in the United States

This publication has 39 references indexed in Scilit:

• Changing Epidemiology of Pneumococcal Meningitis after the Introduction of Pneumococcal Conjugate Vaccine in the United States
  Clinical Infectious Diseases, 2008
• Indirect Effect of Conjugate Vaccine on Adult Carriage ofStreptococcus pneumoniae:An Explanation of Trends in Invasive Pneumococcal Disease
  The Journal of Infectious Diseases, 2006
• Changing Epidemiology of Invasive Pneumococcal Disease Among Older Adults in the Era of Pediatric Pneumococcal Conjugate Vaccine
  Published by American Medical Association (AMA) ,2005
• Impact of a Conjugate Vaccine on Community‐Wide Carriage of NonsusceptibleStreptococcus pneumoniaein Alaska
  The Journal of Infectious Diseases, 2004
• Decline in Invasive Pneumococcal Disease after the Introduction of Protein–Polysaccharide Conjugate Vaccine
  New England Journal of Medicine, 2003
• Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia
  The Pediatric Infectious Disease Journal, 2002
• Efficacy of pneumococcal conjugate vaccines and their effect on carriage and antimicrobial resistance
  The Lancet Infectious Diseases, 2001
• Efficacy of a Pneumococcal Conjugate Vaccine against Acute Otitis Media
  New England Journal of Medicine, 2001
• Policy Statement: Recommendations for the Prevention of Pneumococcal Infections, Including the Use of Pneumococcal Conjugate Vaccine (Prevnar), Pneumococcal Polysaccharide Vaccine, and Antibiotic Prophylaxis
  Pediatrics, 2000
• Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children
  The Pediatric Infectious Disease Journal, 2000